Concomitant Sjögren’s Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis

Table 3

Results of liver enzyme and function testing at the end of observation.

	PBC(N=226)	PBC/SS(N=56)	P value
TB (μmol/L)	16.1(11.4,27.7)	15.4(10.1,30.7)	0.392
ALT (IU/L)	29.0(19.0,45.3)	29.0(21.3,36.8)	0.557
AST (IU/L)	39.5(30.0,58.3)	36.0(30.0,54.5)	0.529
ALP (IU/L)	145.5(111.3,224.5)	131.5(103.3,189.8)	0.176
GGT (IU/L)	53.0(33.8,127.5)	59.0(30.3,94.3)	0.639
Alb (g/L)	42.8(35.0,46.5)	42.7(34.7,46.4)	0.973
PLT (×10^9/L)	126.0(71.8,182.3)	94.0(59.8,175.3)	0.112
INR	1.0(0.9,1.2)	1.0(0.9,1.1)	0.998
Fib-4	3.0(1.8,6.8)	4.0(1.9,8.8)	0.254
APRI	0.9(0.4,1.6)	1.0(0.5,2.1)	0.489

Data are expressed as the median (interquartile range); TB, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; Alb, albumin; PLT, platelet; INR, international normalized ratio; Fib-4, fibrosis score; APRI, aspartate aminotransferase/platelet ratio index; SS, Sjögren’s syndrome; and PBC, primary biliary cholangitis.